Increased risk of chronic liver disease in patients with bipolar disorder: A population-based study

General Hospital Psychiatry

Volumn 42, Issue , 2016, Pages 54-59

  Hsu, Jer Hwa ^a   Chien, I Chia ^b,c   Lin, Ching Heng ^d,e  

^a Chia yi Hospital   (Taiwan)

^b Ministry of Health and Welfare   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^e NATIONAL TAIPEI UNIVERSITY OF NURSING AND HEALTH SCIENCES   (Taiwan)

Author keywords

Analgesic; Bipolar disorder; Chronic liver disease; National Health Insurance; Prevalence; Taiwan

Indexed keywords

ANTIDEPRESSANT AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; ALCOHOLIC FATTY LIVER; ARTICLE; BILIARY CIRRHOSIS; BIPOLAR DISORDER; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; CONTROLLED STUDY; FEMALE; HUMAN; HYPERLIPIDEMIA; INCIDENCE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREVALENCE; RANDOM SAMPLE; SEX DIFFERENCE; TAIWANESE; ADOLESCENT; CHRONIC DISEASE; COMORBIDITY; LIVER DISEASE; TAIWAN; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIPOLAR DISORDER; CHRONIC DISEASE; COMORBIDITY; FEMALE; HUMANS; INCIDENCE; LIVER DISEASES; MALE; MIDDLE AGED; PREVALENCE; TAIWAN; YOUNG ADULT;

EID: 84980322398     PISSN: 01638343     EISSN: 18737714     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2016.07.006     Document Type: Article

References (36)

1. [1] Geoffroy, PA, Etain, B, Scott, J, Henry, C, Jamain, S, Leboyer, M, et al. Reconsideration of bipolar disorder as a developmental disorder: importance of the time of onset. J Physiol Paris 107 (2013), 278–285.
2. [2] Goldstein, BI, Kemp, DE, Soczynska, JK, McIntyre, RS, Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry 70 (2009), 1078–1090.
3. [3] Crump, C, Sundquist, K, Winkleby, MA, Sundquist, J, Comorbidities and mortality in bipolar disorder: a Swedish national cohort study. JAMA Psychiatry 70 (2013), 931–939.
4. [4] Carney, CP, Jones, LE, Medical comorbidity in women and men with bipolar disorders: a population-based controlled study. Psychosom Med 68 (2006), 684–691.
5. [5] Magalhaes, PV, Kapczinski, F, Nierenberg, AA, Deckersbach, T, Weisinger, D, Dodd, S, et al. Illness burden and medical comorbidity in the systematic treatment enhancement program for bipolar disorder. Acta Psychiatr Scand 125 (2012), 303–308.
6. [6] McIntyre, RS, Soczynska, JK, Beyer, JL, Woldeyohannes, HO, Law, CW, Miranda, A, et al. Medical comorbidity in bipolar disorder: re-prioritizing unmet needs. Curr Opin Psychiatry 20 (2007), 406–416.
7. [7] Chien, IC, Chang, KC, Lin, CH, Chou, YJ, Chou, P, Prevalence of diabetes in patients with bipolar disorder in Taiwan: a population-based national health insurance study. Gen Hosp Psychiatry 32 (2010), 577–582.
8. [8] Chien, IC, Lin, CH, Chou, YJ, Chou, P, Risk of hypertension in patients with bipolar disorder in Taiwan: a population-based study. Compr Psychiatry 54 (2013), 687–693.
9. [9] Soreca, I, Fagiolini, A, Frank, E, Houck, PR, Thompson, WK, Kupfer, DJ, Relationship of general medical burden, duration of illness and age in patients with bipolar I disorder. J Psychiatr Res 42 (2008), 956–961.
10. [10] Kemp, DE, Gao, K, Ganocy, SJ, Caldes, E, Feldman, K, Chan, PK, et al. Medical and substance use comorbidity in bipolar disorder. J Affect Disord 116 (2009), 64–69.
11. [11] Vernon, G, Baranova, A, Younossi, ZM, Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34 (2011), 274–285.
12. [12] Nishioji, K, Sumida, Y, Kamaguchi, M, Mochizuki, N, Kobayashi, M, Nishimura, T, et al. Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population, 2011–2012. J Gastroenterol 50 (2015), 95–108.
13. [13] Chen, CH, Huang, MH, Yang, JC, Nien, CK, Yang, CC, Yeh, YH, et al. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of Taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J Clin Gastroenterol 40 (2006), 745–752.
14. [14] Chen, CH, Huang, MH, Yang, JC, Nien, CK, Yang, CC, Yeh, YH, et al. Prevalence and etiology of elevated serum alanine aminotransferase level in an adult population in Taiwan. J Gastroenterol Hepatol 22 (2007), 1482–1489.
15. [15] Chen, YH, Chen, KY, Lin, HC, Non-alcoholic cirrhosis and the risk of stroke: a 5-year follow-up study. Liver Int 31 (2011), 354–360.
16. [16] Edwin, D, Flynn, L, Klein, A, Thuluvath, PJ, Cognitive impairment in alcoholic and nonalcoholic cirrhotic patients. Hepatology 30 (1999), 1363–1367.
17. [17] Fuller, BE, Rodriguez, VL, Linke, A, Sikirica, M, Dirani, R, Hauser, P, Prevalence of liver disease in veterans with bipolar disorder or schizophrenia. Gen Hosp Psychiatry 33 (2011), 232–237.
18. [18] Chinese Hospital Association, ICD-9-CM English–Chinese dictionary. 2000, Chinese Hospital Association Press, Taipei.
19. [19] Chien, IC, Chou, YJ, Lin, CH, Bih, SH, Chou, P, Prevalence of psychiatric disorders among National Health Insurance enrollees in Taiwan. Psychiatr Serv 55 (2004), 691–697.
20. [20] Chien, IC, Hsu, JH, Bih, SH, Lin, CH, Chou, YJ, Lee, CH, et al. Prevalence, correlates, and disease patterns of antipsychotic use in Taiwan. Psychiatry Clin Neurosci 62 (2008), 677–684.
21. [21] Hui, JM, Hodge, A, Farrell, GC, Kench, JG, Kriketos, A, George, J, Beyond insulin resistance in NASH: TNF-alpha or adiponectin ?. Hepatology 40 (2004), 46–54.
22. [22] Hsu, JH, Chien, IC, Lin, CH, Increased risk of hyperlipidemia in patients with bipolar disorder: a population-based study. Gen Hosp Psychiatry 37 (2015), 294–298.
23. [23] Elmslie, JL, Silverstone, JT, Mann, JI, Williams, SM, Romans, SE, Prevalence of overweight and obesity in bipolar patients. J Clin Psychiatry 61 (2000), 179–184.
24. [24] Xiang, YT, Zhang, L, Wang, G, Hu, C, Ungvari, GS, Dickerson, FB, et al. Sociodemographic and clinical features of bipolar disorder patients misdiagnosed with major depressive disorder in China. Bipolar Disord 15 (2013), 199–205.
25. [25] Evans-Lacko, SE, Zeber, JE, Gonzalez, JM, Olvera, RL, Medical comorbidity among youth diagnosed with bipolar disorder in the United States. J Clin Psychiatry 70 (2009), 1461–1466.
26. [26] Sorrentino, P, Tarantino, G, Conca, P, Perrella, A, Terracciano, ML, Vecchione, R, et al. Silent non-alcoholic fatty liver disease-a clinical-histological study. J Hepatol 41 (2004), 751–757.
27. [27] Nery, FG, Miranda-Scippa, A, Nery-Fernandes, F, Kapczinski, F, Lafer, B, Prevalence and clinical correlates of alcohol use disorders among bipolar disorder patients: results from the Brazilian bipolar research network. Compr Psychiatry 55 (2014), 1116–1121.
28. [28] Simhandl, C, Radua, J, Konig, B, Amann, BL, Prevalence and impact of comorbid alcohol use disorder in bipolar disorder: a prospective follow-up study. Aust N Z J Psychiatry 50 (2016), 345–351 [pii: 0004867415585855. Epub ahead of print].
29. [29] Wiley, TE, McCarthy, M, Breidi, L, McCarthy, M, Layden, TJ, Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 28 (1998), 805–809.
30. [30] Kreinin, A, Novitski, D, Rabinowitz, D, Weizman, A, Grinshpoon, A, Association between tobacco smoking and bipolar affective disorder: clinical, epidemiological, cross-sectional, retrospective study in outpatients. Compr Psychiatry 53 (2012), 269–274.
31. [31] de la Monte, S, Derdak, Z, Wands, JR, Alcohol, insulin resistance and the liver–brain axis. J Gastroenterol Hepatol 27 (2012), 33–41.
32. [32] Dumortier, G, Cabaret, W, Stamatiadis, L, Saba, G, Benadhira, R, Rocamora, JF, et al. Hepatic tolerance of atypical antipsychotic drugs. Encephale 28 (2002), 542–551.
33. [33] Ozcanli, T, Erdogan, A, Ozdemir, S, Onen, B, Ozmen, M, Doksat, K, et al. Severe liver enzyme elevations after three years of olanzapine treatment: a case report and review of olanzapine associated hepatotoxicity. Prog Neuropsychopharmacol Biol Psychiatry 30 (2006), 1163–1166.
34. [34] Deutsch, SI, Burket, JA, Rosse, RB, Valproate-induced hyperammonemic encephalopathy and normal liver functions: possible synergism with topiramate. Clin Neuropharmacol 32 (2009), 350–352.
35. [35] Ouellet, G, Tremblay, L, Marleau, D, Fulminant hepatitis induced by lamotrigine. South Med J 102 (2009), 82–84.
36. [36] Voican, CS, Corruble, E, Naveau, S, Perlemuter, G, Antidepressant-induced liver injury: a review for clinicians. Am J Psychiatry 171 (2014), 404–415.